Qinchao Ding

Qinchao Ding

Auto-generated profile, based on publicly available information

Qinchao Ding

School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, PR. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
QDQinchao Ding
Qinchao Ding
APAiwen Pi
Aiwen Pi
LHLiuyi Hao
Liuyi Hao
TXTiantian Xu
Tiantian Xu
QZQin Zhu
Qin Zhu
SLSongtao Li
Songtao Li

1 May 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
QDQinchao Ding
Qinchao Ding
YMYue Ma
Yue Ma
SLShanglei Lai
Shanglei Lai
XDXiaobing Dou
Xiaobing Dou
SLSongtao Li
Songtao Li

1 February 2020 in Journal of Functional Foods
Verified
Journal Article
Open access
XDXiaobing Dou
Xiaobing Dou
QDQinchao Ding
Qinchao Ding
SLShanglei Lai
Shanglei Lai
FJFusheng Jiang
Fusheng Jiang
QSQing Song
Qing Song
SLSongtao Li
Songtao Li

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WYWenwen Yang
Wenwen Yang
LZLinwensi Zhu
Linwensi Zhu
SLShanglei Lai
Shanglei Lai
QDQinchao Ding
Qinchao Ding
TXTiantian Xu
Tiantian Xu
SLSongtao Li
Songtao Li
Objective. Hepatic metabolic disorder induced by lipotoxicity plays a detrimental role in metabolic fatty liver disease pathogenesis. Cimifugin (Cim), a coumarin derivative extracted from the root of Saposhnikovia divaricata, possesses multiple biological properties against inflammation, allergy, and oxidative stress. However, limited study has addressed the hepatoprotective role of Cim. Here, we investigate the protective effect of Cim against lipotoxicity‐induced cytotoxicity and steatosis in hepatocytes and clarify its potential mechanisms. Methods. AML‐12, a nontransformed mouse hepatocyte cell line, was employed in this study. The cells were incubated with palmitate or oleate to imitate hepatotoxicity or steatosis model, respectively. Results. Cim significantly reversed palmitate‐induced hepatocellular injury in a dose‐dependent manner, accompanied by improvements in oxidative stress and mitochondrial damage. Cim pretreatment reversed palmitate‐stimulated TLR4/p38 MAPK activation and SIRT1 reduction without affecting JNK, ERK1/2, and AMPK pathways. The hepatoprotective effects of Cim were abolished either through activating TLR4/p38 by their pharmacological agonists or genetical silencing SIRT1 via special siRNA, indicating a mechanistic involvement. Moreover, Cim treatment improved oleate‐induced hepatocellular lipid accumulation, which could be blocked by either TLR4 stimulation or SIRT1 knockdown. We observed that SIRT1 was a potential target of TLR4 in palmitate‐treated hepatocytes, since TLR4 agonist LPS aggravated, whereas TLR4 antagonist CLI‐095 alleviated palmitate‐decreased SIRT1 expression. SIRT1 knockdown did not affect palmitate‐induced TLR4. In addition, TLR4 activation by LPS significantly abolished Cim‐protected SIRT1 reduction induced by palmitate. These results collaboratively indicated that TLR4‐regulated SIRT1 pathways was mechanistically involved in the protective effects of Cim against lipotoxicity. Conclusion. In brief, we demonstrate the protective effects of Cim against lipotoxicity‐induced cell death and steatosis in hepatocytes. TLR4‐regulated p38 MAPK and SIRT1 pathways are involved in Cim‐protected hepatic lipotoxicity. Cim is a potential candidate for improving hepatic metabolic disorders mediated by lipotoxicity.

9 February 2023 in Hepatology Communications
Verified
Journal Article
Open access
QSQing Song
Qing Song
YCYingli Chen
Yingli Chen
QDQinchao Ding
Qinchao Ding
AGAlexandra Griffiths
Alexandra Griffiths
LLLifeng Liu
Lifeng Liu
ZSZhenyuan Song
Zhenyuan Song
Background: Adipose tissue thermogenic activities use fatty acids from lipolysis for heat generation. Therefore, a tight coupling between lipolysis and thermogenesis is physiologically imperative in maintaining not only body temperature but also lipids homeostasis. Adipose tissue dysfunction contributes to alcoholic liver disease (ALD). Here, studies were conducted to examine how alcohol intake affects adipose tissue thermogenic activities and whether altered adipose tissue thermogenesis contributes to ALD. Methods: Both the Lieber-DeCarli and the NIAAA mouse models of ALD were used. Denervation surgery in epididymal fat pads was performed. CL316,243, a selective β3-adrenoceptor agonist, SR59230A, a selective β3 adrenoceptor (ADRB3) antagonist, and rapamycin, a selective mechanistic target of rapamycin complex 1 (mTORC1) inhibitor, were administrated through i.p. injection. Adipocyte-specific Prdm16 knockout mice were subjected to alcohol-containing diet chronically. Results: Chronic alcohol consumption, which enhances adipose tissue lipolysis, inhibits thermogenic activities of beige adipocytes in inguinal white adipose tissue (WAT), leading to an uncoupling status between lipolysis and thermogenesis in WAT at both basal and ADRB3 stimulation states. CL316,243 administration exacerbates liver pathologies of ALD. Alcohol intake inhibits mTORC1 activities in WAT. In mice, mTORC1 inhibition by rapamycin inhibits the thermogenesis of iWAT, whereas enhancing WAT lipolysis. Further investigations using adipocyte-specific Prdm16 knockout mice revealed that functional deficiency of beige adipocytes aggravates liver pathologies of ALD, suggesting that the inhibitory effect of alcohol on WAT browning/thermogenesis contributes to ALD pathogenesis. Conclusion: Chronic alcohol consumption induces an “uncoupling status” between lipolysis and browning/thermogenesis in WAT by inhibiting mTORC1 activation. Diminished WAT browning/thermogenesis, concomitant with enhanced lipolysis, contributes to ALD pathogenesis.

27 June 2025 in Science Advances
Verified
Journal Article
Open access
QDQinchao Ding
Qinchao Ding
FCFeiwei Cao
Feiwei Cao
HZHui Zhuge
Hui Zhuge
SLShanglei Lai
Shanglei Lai
WCWenjing Cao
Wenjing Cao
SLSongtao Li
Songtao Li
Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), a nicotinamide adenine dinucleotide (NAD + ) synthetase in Preiss-Handler and salvage pathways, governs nuclear NAD + homeostasis. This study investigated the role of NMNAT1 in alcohol-associated liver disease (ALD). Decreased NMNAT1 expression and activity were observed in the liver of patients with alcohol-associated hepatitis and either liver or primary hepatocytes from ALD mice. F-box and WD repeat domain containing 7 (FBXW7)–regulated interferon regulatory factor 1 (IRF1) ubiquitination degradation contributed to the alcohol-inhibited NMNAT1 transcriptional level. Hepatic NMNAT1 knockout aggravated alcohol-induced hepatic NAD + decline and further hepatic steatosis and liver injury. Metabolomics and transcriptomics interaction revealed that the cysteine sulfinic acid decarboxylase (CSAD)–regulated taurine pathway was involved in NMNAT1-disrupted hepatic lipid metabolism in ALD. Hepatic CSAD overexpression or taurine supply attenuated hepatic NMNAT1 knockout–aggravated ALD. Hepatic NMNAT1 loss inhibited NMN-protected ALD. Replenishing hepatic NMNAT1 reversed liver lipid accumulation in ALD mice. These findings identified NMNAT1 as a promising therapeutic target for ALD.